The notices it replaced
- Reissues: PAR-21-330 Utilizing the PLCO Biospecimens Resource to Bridge Gaps in Cancer Etiology and Early Detection Research (U01 Clinical Trial Not Allowed)
- 2 steps back: PAR-18-913 Utilizing the PLCO Biospecimens Resource to Bridge Gaps in Cancer Etiology and Early Detection Research (U01 Clinical Trial Not Allowed)
- 3 steps back: PAR-15-297 Utilizing the PLCO Biospecimens Resource to Bridge Gaps in Cancer Etiology and Early Detection Research (U01)
- 4 steps back: PAR-13-036 Utilizing the PLCO Biospecimens Resource to Bridge Gaps in Cancer Etiology and Early Detection Research (U01)
Who won it before
23 competing awards (new and renewals) from FY2014 to FY2025 under this notice and the notices it replaced: $13,438,852 in first-year total cost, median $613,236.
Most frequent study sections
- Special Emphasis Panel[ZCA1 SRLB-5 (O1)]4
- Special Emphasis Panel[ZCA1 RTRB-F (M1)]3
- Special Emphasis Panel[ZCA1 TCRB-T (M1)]3
- Special Emphasis Panel[ZCA1 TCRB-Y (O1)]3
- Special Emphasis Panel[ZCA1 RPRB-6 (O2)]2
Most frequent institutions
- UNIVERSITY OF TX MD ANDERSON CAN CTR4
- FRED HUTCHINSON CANCER RESEARCH CENTER2
- MASSACHUSETTS GENERAL HOSPITAL2
- NEW YORK UNIVERSITY SCHOOL OF MEDICINE2
- UNIVERSITY OF CHICAGO2
| FY | Project | PIs | Institution | First-year cost | Study section |
|---|---|---|---|---|---|
| 2025 | A non-invasive blood test for multi-cancer detection and determination of tissue of origin preceding overt cancer diagnosis1U01CA297685-01 · under PAR-21-330 | BISSONNETTE, BRUCE MARCZHANG, WEI | UNIVERSITY OF CHICAGO, IL | $692,491 | ZCA1 |
| 2025 | 5mC and 5hmC DNA alterations as sensitive and specific biomarkers for the non-invasive early detection of pancreatic ductal adenocarcinoma1U01CA296639-01A1 · under PAR-21-330 | GOEL, AJAY | BECKMAN RESEARCH INSTITUTE/CITY OF HOPE, CA | $690,637 | ZCA1 |
| 2025 | Validation of blood-based biomarkers for risk assessment of lung cancer among individuals with no smoking history in the PLCO Cohort1U01CA295902-01A1 · under PAR-21-330 | OSTRIN, EDWIN JUSTIN | UNIVERSITY OF TX MD ANDERSON CAN CTR, TX | $525,013 | ZCA1 |
| 2024 | Single-molecule nanopore-based identification of methylome signatures in cfDNA for early colorectal cancer detection1U01CA282212-01A1 · under PAR-21-330 | JI, HANLEE PLAU, BILLY TSZ CHEONG | STANFORD UNIVERSITY, CA | $639,780 | ZCA1 |
| 2023 | Blood-Based Biomarkers for Personalized Risk Assessment of Breast and Ovarian Cancer1U01CA282216-01 · under PAR-21-330 | FAHRMANN, JOHANNES F | UNIVERSITY OF TX MD ANDERSON CAN CTR, TX | $672,298 | ZCA1 |
| 2023 | Analysis of the predictability of lung cancer using DNA Repair functional assays and cryopreserved blood samples of the PLCO prospective cohort1U01CA279001-01 · under PAR-21-330 | LIVNEH, ZVI | WEIZMANN INSTITUTE OF SCIENCE | $191,085 | ZCA1 |
| 2022 | Molecular prediction of myeloma in African Americans1U01CA271492-01 · under PAR-18-913 | GHOBRIAL, IRENE M. | DANA-FARBER CANCER INST, MA | $892,457 | ZCA1 |
| 2022 | Homologous recombination repair capacity in peripheral blood lymphocytes as a breast cancer risk factor1U01CA260731-01A1 · under PAR-18-913 | LIU, SONGZHAO, HUAZHU, QIANQIAN | VIRGINIA COMMONWEALTH UNIVERSITY, VA | $512,284 | ZCA1 |
| 2022 | Influence of intra-individual variability in serial screening samples on clinical decision-making for risk stratification and biopsy by a single PSA and additional markers1U01CA266535-01A1 · under PAR-18-913 | CARLSSON, SIGRID | SLOAN-KETTERING INST CAN RESEARCH, NY | $463,832 | ZCA1 |
| 2021 | Longitudinal Proteomic and Metabolomic Predictors of Pancreatic Cyst Malignant Progression and Early Stage Pancreatic Cancer1U01CA239522-01A1 · under PAR-18-913 | SCHMIDT, CHRISTIAN MAXIMILLIANZHANG, JIANJUN | INDIANA UNIVERSITY INDIANAPOLIS, IN | $677,787 | ZCA1 |
| 2021 | The Oral Mycobiome and Risk of Pancreatic Cancer1U01CA250186-01A1 · under PAR-18-913 | AHN, JIYOUNGHAYES, RICHARD BERNARD | NEW YORK UNIVERSITY SCHOOL OF MEDICINE, NY | $646,256 | ZCA1 |
| 2021 | Proteomic Analyses of Serial Prediagnostic PLCO Serum in Cases and Controls to Identify Early Detection Ovarian Cancer Biomarkers Rising in a Substantial Fraction of Cases and Stable in Most Controls1U01CA260758-01 · under PAR-18-913 | SKATES, STEVEN J | MASSACHUSETTS GENERAL HOSPITAL, MA | $546,231 | ZCA1 |
| 2019 | Colorectal cancer risk factors, risk prediction and blood-based biomarker by tumor consensus molecular subtype1U01CA222163-01A1 · under PAR-15-297 | BRESALIER, ROBERT SDAVIS, JENNIFER SARAH | UNIVERSITY OF TX MD ANDERSON CAN CTR, TX | $448,631 | ZCA1 |
| 2017 | Development of 5hmC and 5mC biomarkers in cell-free circulating DNA for sensitive colon cancer detection and prognosis1U01CA217078-01 · under PAR-15-297 | BISSONNETTE, BRUCE MARCZHANG, WEI | UNIVERSITY OF CHICAGO, IL | $613,236 | ZCA1 |
| 2016 | Incorporating Biomarkers to Improve Lung Cancer Risk Prediction1U01CA194733-01A1 · under PAR-13-036 | FENG, ZIDINGHANASH, SAMIR MTAMMEMAGI, MARTIN C | UNIVERSITY OF TX MD ANDERSON CAN CTR, TX | $692,318 | ZCA1 |
| 2015 | Molecular Risk Stratification for Colonoscopic Surveillance1U01CA182367-01A1 · under PAR-13-036 | CHAN, ANDREW T | MASSACHUSETTS GENERAL HOSPITAL, MA | $656,638 | ZCA1 |
| 2014 | Colorectal Tumor Risk Prediction in the PLCO Trial1U01CA185094-01A1 · under PAR-13-036 | PETERS, ULRIKE | FRED HUTCHINSON CANCER RESEARCH CENTER, WA | $736,996 | ZCA1 |
| 2014 | Translating gene-calcium interactions to precision medicine for colorectal cancer1U01CA182364-01 · under PAR-13-036 | DAI, QIEDWARDS, TODD L | VANDERBILT UNIVERSITY, TN | $635,725 | ZCA1 |
| 2014 | 15-Hydroxyprostaglandin Dehydrogenase, NSAIDs, Vitamin D, and Coloretcal Neoplasi1U01CA181770-01 · under PAR-13-036 | LI, LI | CASE WESTERN RESERVE UNIVERSITY, OH | $561,786 | ZCA1 |
| 2014 | Oral microbiome in esophageal adenocarcinoma1U01CA182370-01 · under PAR-13-036 | AHN, JIYOUNGPEI, ZHIHENG | NEW YORK UNIVERSITY SCHOOL OF MEDICINE, NY | $539,256 | ZCA1 |
| 2014 | Varicella virus antigens in glioma etiology and survival1U01CA182371-01 · under PAR-13-036 | WIEMELS, JOSEPH LEO | UNIVERSITY OF CALIFORNIA, SAN FRANCISCO, CA | $535,578 | ZCA1 |
| 2014 | Validation of findings from the Epigenome-Wide Association Study of Breast Cancer1U01CA184910-01A1 · under PAR-13-036 | STURGEON, SUSAN R | UNIVERSITY OF MASSACHUSETTS AMHERST, MA | $518,726 | ZCA1 |
| 2014 | Proteomic, Glycomic and Autoantibody Lung Cancer Biomarker Validation1U01CA185097-01 · under PAR-13-036 | HOUGHTON, A MCGARRYLAMPE, PAUL D. | FRED HUTCHINSON CANCER RESEARCH CENTER, WA | $349,811 | ZCA1 |
Data: Grants.gov's daily extract and NIH's notice pages and award files, in ScienceGraph release conductgrants-2026-11-09-0.1.0. An award is listed only where NIH's own record names the notice, and a PI only by NIH's profile ID. Grants.gov and NIH do not endorse ScienceDex.